{"classes":[{"categories":[{"measurements":[{"comment":"Median and 95% CI was not estimated because of insufficient number of participants with the event.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"7.75","upperLimit":"13.21","value":"11.24"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"152"}],"units":"Participants"}],"description":"OS: a) C1071003 Cohort A: OS was defined as time from the date of the first dose until death due to any cause; B) Flatiron Cohort: OS was defined as time from initiation of the first line after participant identified as having TCR MM until the date of death due to any cause. Kaplan Meier Method was used for analysis. Participants without an event were censored at the latest available record or the data cut-off.","dispersionType":"95% Confidence Interval","groups":[{"description":"Eligible participants with TCR MM, who were BCMA naïve, who were enrolled between 2 February 2021 to 07 January 2022 and who were treated with elranatamab in study C1071003 were included.","id":"OG000","title":"C1071003 Cohort A"},{"description":"Eligible participants with TCR MM who were treated with SOC therapies in real world clinical practice setting, identified from Flatiron Health database were included. This arm served as external control arm.","id":"OG001","title":"RWD: Flatiron Health"}],"paramType":"MEDIAN","populationDescription":"Eligible participants whose data was retrieved and was used in this retrospective cohort study.","reportingStatus":"POSTED","timeFrame":"C1071003: The date of the first dose until death due to any cause or censoring (maximum up to 15 months); Flatiron: First line after participant identified as having TCR MM until the date of death due to any cause or censoring (maximum of 66.9 months)","title":"OS: Study C1071003 Cohort A Versus Flatiron Cohort - Using Unweighted Analysis","type":"SECONDARY","unitOfMeasure":"Months"}